Publication | Closed Access

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

AsthmaCxcr2 AntagonistAllergyUncontrolled Persistent AsthmaClinical TrialsPlacebo-controlled TrialPharmacotherapyPharmacologic InterventionMedicinePulmonary Disease